Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management
Jay W Mason,1 Thomas E Moon2 1School of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc, Emeryville, CA, USA Abstract: 5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-07-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/use-and-cardiovascular-safety-of-transdermal-and-other-granisetron-pre-a13822 |
| Summary: | Jay W Mason,1 Thomas E Moon2 1School of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc, Emeryville, CA, USA Abstract: 5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class. Keywords: chemotherapy-induced nausea, vomiting, granisetron, QT prolongation |
|---|---|
| ISSN: | 1179-1322 |